{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:01:15Z","timestamp":1790812875835,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009980","name":"Medizinische Universit\u00e4t Innsbruck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009980","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.urolonc.2019.11.007","type":"journal-article","created":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T21:05:20Z","timestamp":1579035920000},"page":"129-136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Treatment of non-metastatic castration resistant prostate cancer in 2020: What is the best?"],"prefix":"10.1016","volume":"38","author":[{"given":"Isabel","family":"Heidegger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian P.","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias M.","family":"Heck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.urolonc.2019.11.007_bib0001","first-page":"232","article-title":"Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"22","author":"Huggins","year":"1972","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.urolonc.2019.11.007_bib0002","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.eururo.2017.06.002","article-title":"Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017","volume":"73","author":"Gillessen","year":"2018","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2019.11.007_bib0003","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG guidelines on Prostate Cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur Urol"},{"issue":"13","key":"10.1016\/j.urolonc.2019.11.007_bib0004","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2005.01.529","article-title":"Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer","volume":"23","author":"Smith","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2019.11.007_bib0005","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11523-016-0461-6","article-title":"New biomarkers for selecting the best therapy regimens in metastatic castration-resistant prostate cancer","volume":"12","author":"Heidegger","year":"2017","journal-title":"Target Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2019.11.007_bib0006","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.eururo.2018.03.028","article-title":"Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology","volume":"75","author":"Nuhn","year":"2019","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.urolonc.2019.11.007_bib0007","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1002\/cncr.25762","article-title":"Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer","volume":"117","author":"Smith","year":"2011","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.urolonc.2019.11.007_bib0008","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.urology.2009.12.057","article-title":"Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer","volume":"76","author":"Lodde","year":"2010","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.urolonc.2019.11.007_bib0009","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.juro.2008.05.045","article-title":"Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade","volume":"180","author":"Suzuki","year":"2008","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2019.11.007_bib0010","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/0008-5472.CAN-11-3948","article-title":"ARN-509: a novel antiandrogen for prostate cancer treatment","volume":"72","author":"Clegg","year":"2012","journal-title":"Cancer Res"},{"issue":"15","key":"10.1016\/j.urolonc.2019.11.007_bib0011","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.urolonc.2019.11.007_bib0012","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/S1470-2045(18)30456-X","article-title":"Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial","volume":"19","author":"Saad","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2019.11.007_bib0013","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.eururo.2017.08.012","article-title":"Moving towards precision urologic oncology: targeting enzalutamide-resistant prostate cancer and mutated forms of the androgen receptor using the novel inhibitor darolutamide (ODM-201)","volume":"73","author":"Borgmann","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2019.11.007_bib0014","doi-asserted-by":"crossref","first-page":"12007","DOI":"10.1038\/srep12007","article-title":"Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies","volume":"5","author":"Moilanen","year":"2015","journal-title":"Sci Rep"},{"issue":"13","key":"10.1016\/j.urolonc.2019.11.007_bib0015","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N Engl J Med"},{"issue":"5928","key":"10.1016\/j.urolonc.2019.11.007_bib0016","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.1168175","article-title":"Development of a second-generation antiandrogen for treatment of advanced prostate cancer","volume":"324","author":"Tran","year":"2009","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.urolonc.2019.11.007_bib0017","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.urolonc.2019.11.007_bib0018","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.urolonc.2019.11.007_bib0019","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1200\/JCO.2015.64.9285","article-title":"Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE Trial","volume":"34","author":"Penson","year":"2016","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.urolonc.2019.11.007_bib0020","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.urolonc.2019.11.007_bib0021","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1056\/NEJMp1805966","article-title":"Metastasis-free survival\u2014a new end point in Prostate Cancer Trials","volume":"378","author":"Beaver","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.urolonc.2019.11.007_bib0022","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1634\/theoncologist.2009-0290","article-title":"Polypharmacy in older adults with cancer","volume":"15","author":"Maggiore","year":"2010","journal-title":"Oncologist"},{"issue":"19","key":"10.1016\/j.urolonc.2019.11.007_bib0023","first-page":"30154","article-title":"Drug-Drug Interactions in Prostate Cancer Treatment","volume":"S1558-7673","author":"Hebenstreit","year":"2019","journal-title":"Clin Genitourin Cancer"},{"issue":"7","key":"10.1016\/j.urolonc.2019.11.007_bib0024","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.urolonc.2019.11.007_bib0025","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2019.11.007_bib0026","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.juro.2015.12.025","article-title":"Diagnostic efficacy of (68)gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer","volume":"195","author":"Maurer","year":"2016","journal-title":"J Urol"},{"issue":"12","key":"10.1016\/j.urolonc.2019.11.007_bib0027","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1007\/s00259-016-3435-0","article-title":"Comparison of bone scintigraphy and (68)Ga-PSMA PET for skeletal staging in prostate cancer","volume":"43","author":"Pyka","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.urolonc.2019.11.007_bib0028","author":"Perera","year":"2019","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2019.11.007_bib0029","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.eururo.2018.01.006","article-title":"Efficacy, predictive factors, and prediction nomograms for (68)Ga-labeled prostate-specific membrane antigen-ligand positron-emission tomography\/computed tomography in early biochemical recurrent prostate cancer after radical prostatectomy","volume":"73","author":"Rauscher","year":"2018","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2019.11.007_bib0030","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00259-015-3240-1","article-title":"Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET\/CT in relation to PSA levels, PSA doubling time and Gleason score","volume":"43","author":"Verburg","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.urolonc.2019.11.007_bib0031","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0090-4295(96)00184-7","article-title":"Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy","volume":"48","author":"Wright","year":"1996","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2019.11.007_bib0032","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-19-1050","article-title":"Prostate-specific membrane antigen ligand positron-emission tomography in men with nonmetastatic castration-resistant prostate cancer","author":"Fendler","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.urolonc.2019.11.007_bib0033","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41391-017-0007-8","article-title":"The use of PET\/CT in prostate cancer","volume":"21","author":"Li","year":"2018","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urolonc.2019.11.007_bib0034","doi-asserted-by":"crossref","DOI":"10.1177\/1179554919833927","article-title":"The current landscape of treatment in non-metastatic castration-resistant prostate cancer","volume":"13","author":"El-Amm","year":"2019","journal-title":"Clin Med Insights Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2019.11.007_bib0035","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41391-018-0078-1","article-title":"Non-metastatic castration resistant prostate cancer: a review of current and emerging medical therapies","volume":"22","author":"Alpajaro","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"10.1016\/j.urolonc.2019.11.007_bib0036","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.juro.2018.03.125","article-title":"The IMAAGEN study: effect of abiraterone acetate and prednisone on prostate specific antigen and radiographic disease progression in patients with nonmetastatic castration resistant prostate cancer","volume":"200","author":"Ryan","year":"2018","journal-title":"J Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143919304806?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143919304806?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:16:32Z","timestamp":1761041792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143919304806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S1078143919304806"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2019.11.007","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of non-metastatic castration resistant prostate cancer in 2020: What is the best?","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2019.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}